372 related articles for article (PubMed ID: 14974863)
1. Cytokeratin subtypes in thyroid tumours: immunohistochemical study with emphasis on the follicular variant of papillary carcinoma.
Cameron BR; Berean KW
J Otolaryngol; 2003 Oct; 32(5):319-22. PubMed ID: 14974863
[TBL] [Abstract][Full Text] [Related]
2. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution.
Sahoo S; Hoda SA; Rosai J; DeLellis RA
Am J Clin Pathol; 2001 Nov; 116(5):696-702. PubMed ID: 11710686
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical diagnosis of papillary thyroid carcinoma.
Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
[TBL] [Abstract][Full Text] [Related]
4. [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis].
He CN; He L; Cheng JQ; Chen SC; Zhao HF; Zhai JP; Zhang J
Zhonghua Bing Li Xue Za Zhi; 2008 Jan; 37(1):35-9. PubMed ID: 18509983
[TBL] [Abstract][Full Text] [Related]
5. Trefoil factor 3 immunohistochemical characterization of follicular thyroid lesions from tissue microarray.
Patel MR; Bryson PC; Shores CG; Hart CF; Thorne LB; Deal AM; Zanation AM
Arch Otolaryngol Head Neck Surg; 2009 Jun; 135(6):590-6. PubMed ID: 19528408
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility.
Baloch ZW; Abraham S; Roberts S; LiVolsi VA
Hum Pathol; 1999 Oct; 30(10):1166-71. PubMed ID: 10534163
[TBL] [Abstract][Full Text] [Related]
7. Hyalinizing trabecular adenoma of the thyroid revisited: a histologic and immunohistochemical study of thyroid lesions with prominent trabecular architecture and sclerosis.
Galgano MT; Mills SE; Stelow EB
Am J Surg Pathol; 2006 Oct; 30(10):1269-73. PubMed ID: 17001158
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
9. The absence of CD56 expression can differentiate papillary thyroid carcinoma from other thyroid lesions.
Golu I; Vlad MM; Dema A; Moleriu LC; Tudor A; Iacob M; Popa O; Cornianu M
Indian J Pathol Microbiol; 2017; 60(2):161-166. PubMed ID: 28631628
[TBL] [Abstract][Full Text] [Related]
10. CXC motif ligand 12 as a novel diagnostic marker for papillary thyroid carcinoma.
Chung SY; Park ES; Park SY; Song JY; Ryu HS
Head Neck; 2014 Jul; 36(7):1005-12. PubMed ID: 23784811
[TBL] [Abstract][Full Text] [Related]
11. CD57 (Leu-7) expression is helpful in diagnosis of the follicular variant of papillary thyroid carcinoma.
Khan A; Baker SP; Patwardhan NA; Pullman JM
Virchows Arch; 1998 May; 432(5):427-32. PubMed ID: 9645441
[TBL] [Abstract][Full Text] [Related]
12. Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases.
Yu XM; Schneider DF; Leverson G; Chen H; Sippel RS
Thyroid; 2013 Oct; 23(10):1263-8. PubMed ID: 23477346
[TBL] [Abstract][Full Text] [Related]
13. Cytokeratin19 expression discriminates papillary thyroid carcinoma from other thyroid lesions and predicts its aggressive behavior.
Isic Dencic T; Cvejic D; Paunovic I; Tatic S; Havelka M; Savin S
Med Oncol; 2013 Mar; 30(1):362. PubMed ID: 23269585
[TBL] [Abstract][Full Text] [Related]
14. Papillary and follicular neoplasms of the thyroid gland. Differential immunohistochemical staining with high-molecular-weight keratin and involucrin.
Liberman E; Weidner N
Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):42-8. PubMed ID: 10937048
[TBL] [Abstract][Full Text] [Related]
15. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma.
Bose D; Das RN; Chatterjee U; Banerjee U
Indian J Med Paediatr Oncol; 2012 Apr; 33(2):107-11. PubMed ID: 22988353
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma.
Nakamura N; Erickson LA; Jin L; Kajita S; Zhang H; Qian X; Rumilla K; Lloyd RV
Endocr Pathol; 2006; 17(3):213-23. PubMed ID: 17308358
[TBL] [Abstract][Full Text] [Related]
17. Follicular adenoma with papillary architecture: a lesion mimicking papillary thyroid carcinoma.
Mai KT; Landry DC; Thomas J; Burns BF; Commons AS; Yazdi HM; Odell PF
Histopathology; 2001 Jul; 39(1):25-32. PubMed ID: 11454041
[TBL] [Abstract][Full Text] [Related]
18. CK19 IS A USEFUL MARKER IN DISTINGUISHING FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA FROM BENIGN THYROID LESIONS WITH FOLLICULAR GROWTH PATTERN.
Noroozinia F; Gheibi A; Ilkhanizadeh B; Abbasi A
Acta Endocrinol (Buchar); 2016; 12(4):387-391. PubMed ID: 31149120
[TBL] [Abstract][Full Text] [Related]
19. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma.
Tan A; Etit D; Bayol U; Altinel D; Tan S
Ann Diagn Pathol; 2011 Apr; 15(2):108-16. PubMed ID: 21315633
[TBL] [Abstract][Full Text] [Related]
20. CD56, HBME-1 and cytokeratin 19 expressions in papillary thyroid carcinoma and nodular thyroid lesions.
Erdogan-Durmus S; Ozcan D; Yarikkaya E; Kurt A; Arslan A
J Res Med Sci; 2016; 21():49. PubMed ID: 27904595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
